Navigation Links
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
Date:3/18/2009

o the point of ignoring the cautionary statements contained in the very authority cited by OGD as scientific support for its method, as well as the advice of its own experts.
  • When faced with a safety issue identified in Vancocin's labeling and by its own 2008 advisory committee - the potential for systemic absorption of the drug at toxic levels and the need for pharmacokinetic (PK) testing to address that safety issue - OGD again turned away from patients with CDI. Instead, they concluded that PK testing is unnecessary because the drug is not absorbed in healthy patients who are not infected with CDI.
  • By focusing exclusively on the lower GI tract, the December 2008 Draft Guidance fails to account for another indicated use of Vancocin - Staphylococcus aureus GI infections - which occur in both the upper and lower GI tract.
  • OGD's Q1Q2 sameness standard is flawed and incomplete. OGD acknowledges that inactive ingredients may affect product performance, and that the state of knowledge in this area is underdeveloped. However, OGD proposes without explanation that a Q1Q2 standard developed for oral solutions will nonetheless apply to Vancocin, an oral capsule product. Then, OGD backs off the sameness supposedly ensured by the Q1Q2 standard, and permits generic applicants to vary their inactive ingredients in the absence of any standards to evaluate the effect of such variations on the generic product's performance.
  • "OGD's extensive litany of errors and omissions not only required an equally extensive response, but should cause many to question, as we do, whether OGD has abrogated its decision-making role in bioequivalence method development for Vancocin," continued Doyle.

    While ViroPharma's comments note that numerous flaws prevent use of OGD's proposed new BE method for Vancocin, ViroPharma also believes that, even if the new method was valid, OGD's a
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    2. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    3. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    4. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    5. ViroPharma Announces Discontinuation of HCV-796 Development
    6. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    7. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    8. ViroPharma to Present at the Natixis Bleichroeder Conference
    9. ViroPharma to Present at Three Upcoming Healthcare Conferences
    10. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
    11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... MENLO PARK, Calif. , Aug. 27, ... developer of advanced cancer therapeutics , will be ... Rodman & Renshaw Global Investment Conference, sponsored by ... place Tuesday, September 9th at 2:55 p.m. EDT in ... York Palace Hotel in New York City ...
    (Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Orthopedic Soft Tissue ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic Soft ... mass of cells that connect, support, or surround ... tissues such as tendons, ligaments, cartilage, fascia, and ...
    (Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
    Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2
    (Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... filed in U.S. courts on behalf of women who ... uterine morcellation, Bernstein Liebhard LLP reports. According to court ... on August 18th in the U.S. District Court, Northern ... patient who claims the use of a power morcellator ...
    (Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 Picture, ... no, not Holmes and Watson but more of a Mr. ... Glenn Davis, in terms of personalities and world view. This ... The University of Texas at Austin, and Mr. Outside was ... professor’s family physician, his new girlfriend, and a gaggle of ...
    (Date:8/27/2014)... (PRWEB) August 27, 2014 When Jagger was ... call from his mother; one that he credits as one ... His mom had news that she could set him up ... people with disabilities. Jagger took that job, and he has ... Throughout these past two decades, he also worked in school ...
    (Date:8/27/2014)... 2014 The newest Abington Health ... September 8, 2014. This new 15,000 square foot, $5 ... primary care practices and walk-in laboratory services. ... exciting endeavor for Abington Health as the healthcare landscape ... Health. “Establishing a location in Lower Gwynedd allows us ...
    (Date:8/27/2014)... By Amy Norton ... -- People who take part in clinical trials of new ... typical heart patient, a new study confirms. Experts said ... of the American Medical Association , aren,t surprising -- but ... trials are enrolling a more select patient population that is ...
    Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Abington Health Opens New Health Center in Lower Gwynedd 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3
    ... , , , ... 22, 2010 , Forterus, Inc. (Pink Sheets: FTER) announced its results ... CEO, stated, "This has been a transformational year for Forterus and ... believe we have a strong foundation from which to grow our ...
    ... , Jan. 23 Following the announced end of search ... international aid agency Oxfam said: , "The end of search and rescue ... the survivors is the priority now. , "Hundreds of thousands who lost ... latrines to contain the spread of disease. They need shelter and simple ...
    ... less, MRI scans show , SATURDAY, Jan. 23 (HealthDay News) ... have less activity in the frontal lobes of their brain, ... activate a portion of your frontal lobes, the more accurate ... yourself as desirable or better than your peers, the less ...
    ... (PHILADELPHIA) People who are in car crashes ... other injuries at nights or on weekends do not ... disparities as patients who suffer heart attacks, strokes, cardiac ... according to new research from the University of Pennsylvania ...
    ... 2010 A new American Cancer Society report outlines 21 challenges ... of issues to be addressed and expertise needed to reduce ... low- and middle-income nations that are the target of the ... will appear in the January/February issue of CA: A ...
    ... is one of the ten most disabling diseases in the ... financial burden on health services as average life expectancy increases. ... nearly 27 million Americans or 12.1% of the adult population ... 2001 study showed that the disease costs US health services ...
    Cached Medicine News:Health News:Forterus Announces Fiscal Year 2009 Financial Results 2Health News:Forterus Announces Fiscal Year 2009 Financial Results 3Health News:Forterus Announces Fiscal Year 2009 Financial Results 4Health News:Oxfam Relief Efforts Continue In Haiti 2Health News:Self-Image Linked to Activity in Frontal Lobe of Brain 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Cartilage repair can improve life, ease burden on health services 2
    This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
    The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
    ... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
    Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus....
    Medicine Products: